NIPTviewer - Clinical NIPT Data Visualization

1.1 Background and Clinical Context

Non-Invasive Prenatal Testing (NIPT), also known as cell-free DNA (cfDNA) screening, represents a significant advancement in prenatal screening methodology. First introduced clinically in 2011, NIPT analyzes fragments of cell-free DNA circulating in maternal plasma during pregnancy. These DNA fragments originate from both maternal cells and the placental trophoblast (which shares the fetal genome), allowing for detection of fetal chromosomal aneuploidies without invasive procedures.

The cfDNA in maternal plasma consists of short fragments (~166 bp) released during cellular apoptosis. During pregnancy, approximately 10-20% of this cfDNA originates from the placenta (fetal fraction), while the remainder is maternal in origin. The relative proportion of DNA from each chromosome can be precisely quantified using massively parallel sequencing (MPS), enabling detection of chromosomal imbalances.

1.2 Sequencing Methodology

This platform is designed to visualize results from shallow whole-genome sequencing (sWGS) NIPT workflows, such as VeriSeq NIPT. The typical workflow involves:

Sample Collection: Maternal blood draw (typically 10mL) at 10+ weeks gestation
cfDNA Extraction: Isolation of cell-free DNA from plasma fraction
Library Preparation: Generation of sequencing libraries with unique molecular identifiers
Sequencing: Shallow whole-genome sequencing (0.1-0.5x coverage)
Bioinformatics Analysis: Alignment, GC correction, and statistical analysis
Result Generation: Calculation of Z-scores and risk classification

1.3 Key Metrics and Calculations

Normalized Chromosome Value (NCV) / Z-Score

The NCV represents the number of standard deviations by which a sample's chromosome representation deviates from the reference population mean. It is the primary metric for aneuploidy detection.

NCV = (Sample_Ratio - Reference_Mean) / Reference_StdDev

Positive NCV = over-representation (potential trisomy); Negative = under-representation

Interpretation: For a euploid pregnancy, NCV values cluster around 0 (typically |NCV| < 2). Values with |NCV| of 3 or greater are generally considered screen-positive, though clinical interpretation requires consideration of additional factors including fetal fraction and prior probability.

Fetal Fraction (FF)

The proportion of cell-free DNA in maternal plasma originating from the fetal-placental unit. FF is a critical quality metric that directly impacts test sensitivity.

- Minimum threshold: Typically 4% or greater required for reliable results
- Factors affecting FF: Gestational age (increases with GA), maternal weight (decreases with BMI), placental size, sample handling
- Clinical impact: Low FF increases false-negative risk; very high FF may indicate placental abnormality or vanishing twin

Chromosome Ratio

The normalized proportion of reads mapping to a specific chromosome compared to the expected proportion.

Ratio near 1.0 = Euploid | Ratio above 1.0 = Over-representation | Ratio below 1.0 = Under-representation

For trisomy, the expected ratio increase is proportional to fetal fraction: Ratio is approximately 1 + (FF/2) x (1/normal_copies). For example, with 10% FF and trisomy 21, expected Ratio_21 is approximately 1.05.

1.4 Detectable Conditions

Condition	Chromosome	Detection Rate	PPV (General Population)
Trisomy 21 (Down syndrome)	Chr 21	>99%	~80-90%
Trisomy 18 (Edwards syndrome)	Chr 18	>97%	~60-80%
Trisomy 13 (Patau syndrome)	Chr 13	>95%	~40-60%
Sex Chromosome Aneuploidies	Chr X, Y	>95%	Variable

PPV = Positive Predictive Value. Values vary based on maternal age and prior risk.

NIPTviewer Technical Manual